38 related articles for article (PubMed ID: 20226635)
1. Daily serum piperacillin monitoring is advisable in critically ill patients.
Blondiaux N; Wallet F; Favory R; Onimus T; Nseir S; Courcol RJ; Durocher A; Roussel-Delvallez M
Int J Antimicrob Agents; 2010 May; 35(5):500-3. PubMed ID: 20226635
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Capillary Zone Electrophoresis-Tandem Mass Spectrometry Method for Simultaneous Quantification of Eight β-Lactam Antibiotics and Two β-Lactamase Inhibitors in Plasma Samples.
Cizmarova I; Mikus P; Svidrnoch M; Piestansky J
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675486
[TBL] [Abstract][Full Text] [Related]
3.
Guilhaumou R; Chevrier C; Setti JL; Jouve E; Marsot A; Julian N; Blin O; Simeone P; Lagier D; Mokart D; Bruder N; Garnier M; Velly L
Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627709
[TBL] [Abstract][Full Text] [Related]
4. The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
Novy E; Martinière H; Roger C
Antibiotics (Basel); 2023 Mar; 12(4):. PubMed ID: 37107043
[TBL] [Abstract][Full Text] [Related]
5. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
[TBL] [Abstract][Full Text] [Related]
6. Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
Pai Mangalore R; Ashok A; Lee SJ; Romero L; Peel TN; Udy AA; Peleg AY
Clin Infect Dis; 2022 Nov; 75(10):1848-1860. PubMed ID: 35731853
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
Veiga RP; Paiva JA
Crit Care; 2018 Sep; 22(1):233. PubMed ID: 30244674
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
D'Cunha R; Bach T; Young BA; Li P; Nalbant D; Zhang J; Winokur P; An G
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941653
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
[TBL] [Abstract][Full Text] [Related]
11. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.
de With K; Allerberger F; Amann S; Apfalter P; Brodt HR; Eckmanns T; Fellhauer M; Geiss HK; Janata O; Krause R; Lemmen S; Meyer E; Mittermayer H; Porsche U; Presterl E; Reuter S; Sinha B; Strauß R; Wechsler-Fördös A; Wenisch C; Kern WV
Infection; 2016 Jun; 44(3):395-439. PubMed ID: 27066980
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
[TBL] [Abstract][Full Text] [Related]
13. Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study.
Söyüt H; Kaya ED; Beydemir S
Asian Pac J Trop Biomed; 2014 Aug; 4(8):603-9. PubMed ID: 25183328
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
De Waele JJ; Carrette S; Carlier M; Stove V; Boelens J; Claeys G; Leroux-Roels I; Hoste E; Depuydt P; Decruyenaere J; Verstraete AG
Intensive Care Med; 2014 Mar; 40(3):380-7. PubMed ID: 24356862
[TBL] [Abstract][Full Text] [Related]
16. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients.
Gyssens IC; Kern WV; Livermore DM;
Haematologica; 2013 Dec; 98(12):1821-5. PubMed ID: 24323982
[No Abstract] [Full Text] [Related]
17. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
Sime FB; Roberts MS; Peake SL; Lipman J; Roberts JA
Ann Intensive Care; 2012 Jul; 2(1):35. PubMed ID: 22839761
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of antimicrobials.
Roberts JA; Norris R; Paterson DL; Martin JH
Br J Clin Pharmacol; 2012 Jan; 73(1):27-36. PubMed ID: 21831196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
